A Requirement for Gch1 and Tetrahydrobiopterin in Embryonic Development

Overview

Journal Dev Biol

Publisher Elsevier

Specialties Biology
Reproductive Medicine

Date 2015 Jan 6

PMID 25557619

Citations 18

Authors

Gillian Douglas

Ashley B Hale

Mark J Crabtree

Brent J Ryan

Alex Hansler

Katrin Watschinger

Steven S Gross

Craig A Lygate

Nicholas J Alp

Keith M Channon

Affiliations

Soon will be listed here.

Abstract

Introduction: GTP cyclohydrolase I (GTPCH) catalyses the first and rate-limiting reaction in the synthesis of the enzymatic cofactor, tetrahydrobiopterin (BH4). Loss of function mutations in the GCH1 gene lead to congenital neurological diseases such as DOPA-responsive dystonia and hyperphenylalaninemia. However, little is known about how GTPCH and BH4 affects embryonic development in utero, and in particular whether metabolic replacement or supplementation in pregnancy is sufficient to rescue genetic GTPCH deficiency in the developing embryo.

Methods And Results: Gch1 deficient mice were generated by the insertion of loxP sites flanking exons 2-3 of the Gch1 gene. Gch1(fl/fl) mice were bred with Sox2cre mice to generate mice with global Gch1 deficiency. Genetic ablation of Gch1 caused embryonic lethality by E13.5. Despite loss of Gch1 mRNA and GTPCH enzymatic activity, whole embryo BH4 levels were maintained until E11.5, indicating sufficient maternal transfer of BH4 to reach this stage of development. After E11.5, Gch1(-/-) embryos were deficient in BH4, but an unbiased metabolomic screen indicated that the lethality was not due to a gross disturbance in metabolic profile. Embryonic lethality in Gch1(-/-) embryos was not caused by structural abnormalities, but was associated with significant bradycardia at E11.5. Embryonic lethality was not rescued by maternal supplementation of BH4, but was partially rescued, up to E15.5, by maternal supplementation of BH4 and l-DOPA.

Conclusion: These findings demonstrate a requirement for Gch1 in embryonic development and have important implications for the understanding of pathogenesis and treatment of genetic BH4 deficiencies, as well as the identification of new potential roles for BH4.

Citing Articles

The Emerging Scenario of Ferroptosis in Pancreatic Cancer Tumorigenesis and Treatment.

Lyu H, Kong J, Chen J, Zhang R, Xiao S, Guo D Int J Mol Sci. 2025; 25(24.

PMID: 39769097 PMC: 11727763. DOI: 10.3390/ijms252413334.

Ferroptosis as an emerging target in sickle cell disease.

Fortuna V, Lima J, Oliveira G, Oliveira Y, Getachew B, Nekhai S Curr Res Toxicol. 2024; 7:100181.

PMID: 39021403 PMC: 11252799. DOI: 10.1016/j.crtox.2024.100181.

Tetrahydrobiopterin metabolism attenuates ROS generation and radiosensitivity through LDHA S-nitrosylation: novel insight into radiogenic lung injury.

Feng Y, Feng Y, Gu L, Mo W, Wang X, Song B Exp Mol Med. 2024; 56(5):1107-1122.

PMID: 38689083 PMC: 11148139. DOI: 10.1038/s12276-024-01208-z.

BH4 supplementation reduces retinal cell death in ischaemic retinopathy.

Edgar K, Cunning C, Gardiner T, McDonald D Sci Rep. 2023; 13(1):21292.

PMID: 38042898 PMC: 10693630. DOI: 10.1038/s41598-023-48167-5.

Ninety-six-hour starved peripheral blood mononuclear cell supernatant inhibited LA7 breast cancer stem cells induced tumor reduction in angiogenesis and alternations in and expressions.

Mehri M, Gheitasi R, Pourbagher R, Ranaee M, Nayeri K, Mostafa Rahimi S Front Immunol. 2023; 13:1025933.

PMID: 36908807 PMC: 9996193. DOI: 10.3389/fimmu.2022.1025933.

References

Thomas S, Matsumoto A, Palmiter R . Noradrenaline is essential for mouse fetal development. Nature. 1995; 374(6523):643-6. DOI: 10.1038/374643a0. View

Hefler L, Reyes C, OBrien W, Gregg A . Perinatal development of endothelial nitric oxide synthase-deficient mice. Biol Reprod. 2001; 64(2):666-73. DOI: 10.1095/biolreprod64.2.666. View

Ponzone A, Blau N, Guardamagna O, Ferrero G, Dianzani I, Endres W . Progression of 6-pyruvoyl-tetrahydropterin synthase deficiency from a peripheral into a central phenotype. J Inherit Metab Dis. 1990; 13(3):298-300. DOI: 10.1007/BF01799379. View

McDonald J, Bode V . Hyperphenylalaninemia in the hph-1 mouse mutant. Pediatr Res. 1988; 23(1):63-7. DOI: 10.1203/00006450-198801000-00014. View

Kobayashi K, Morita S, Sawada H, Mizuguchi T, Yamada K, Nagatsu I . Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem. 1995; 270(45):27235-43. DOI: 10.1074/jbc.270.45.27235. View

Furukawa Y, Kish S, Bebin E, Jacobson R, Fryburg J, Wilson W . Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol. 1998; 44(1):10-6. DOI: 10.1002/ana.410440107. View

van der Heijden O, Essers Y, Fazzi G, Peeters L, De Mey J, van Eys G . Uterine artery remodeling and reproductive performance are impaired in endothelial nitric oxide synthase-deficient mice. Biol Reprod. 2005; 72(5):1161-8. DOI: 10.1095/biolreprod.104.033985. View

Thony B, Blau N . Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006; 27(9):870-8. DOI: 10.1002/humu.20366. View

Crabtree M, Tatham A, Al-Wakeel Y, Warrick N, Hale A, Cai S . Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem. 2008; 284(2):1136-44. DOI: 10.1074/jbc.M805403200. View

10.

Katusic Z, Duscio L, Nath K . Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci. 2008; 30(1):48-54. PMC: 2637534. DOI: 10.1016/j.tips.2008.10.003. View

11.

Vasquez-Vivar J, Whitsett J, Derrick M, Ji X, Yu L, Tan S . Tetrahydrobiopterin in the prevention of hypertonia in hypoxic fetal brain. Ann Neurol. 2009; 66(3):323-31. PMC: 2785106. DOI: 10.1002/ana.21738. View

12.

Watschinger K, Keller M, Golderer G, Hermann M, Maglione M, Sarg B . Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc Natl Acad Sci U S A. 2010; 107(31):13672-7. PMC: 2922233. DOI: 10.1073/pnas.1002404107. View

13.

Cunnington C, Channon K . Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart. 2010; 96(23):1872-7. DOI: 10.1136/hrt.2009.180430. View

14.

Opladen T, Hoffmann G, Horster F, Hinz A, Neidhardt K, Klein C . Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord. 2010; 26(1):157-61. DOI: 10.1002/mds.23329. View

15.

Smart N, Dube K, Riley P . Identification of Thymosin β4 as an effector of Hand1-mediated vascular development. Nat Commun. 2010; 1:46. PMC: 2963826. DOI: 10.1038/ncomms1041. View

16.

Werner E, Blau N, Thony B . Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011; 438(3):397-414. DOI: 10.1042/BJ20110293. View

17.

Costigan M, Latremoliere A, Woolf C . Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr Opin Pharmacol. 2011; 12(1):92-9. PMC: 3288148. DOI: 10.1016/j.coph.2011.10.019. View

18.

Du J, Teng R, Lawrence M, Guan T, Xu H, Ge Y . The protein partners of GTP cyclohydrolase I in rat organs. PLoS One. 2012; 7(3):e33991. PMC: 3313957. DOI: 10.1371/journal.pone.0033991. View

19.

Bruggemann N, Spiegler J, Hellenbroich Y, Opladen T, Schneider S, Stephani U . Beneficial prenatal levodopa therapy in autosomal recessive guanosine triphosphate cyclohydrolase 1 deficiency. Arch Neurol. 2012; 69(8):1071-5. DOI: 10.1001/archneurol.2012.104. View

20.

Opladen T, Hoffmann G, Blau N . An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012; 35(6):963-73. DOI: 10.1007/s10545-012-9506-x. View